GO:0005149 interleukin-1 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005149 interleukin-1 receptor binding is a molecular function describing the binding of a ligand to any interleukin-1 receptor, including IL-1R1, IL-1R2 and IL-1RAP.
• The interleukin-1 (IL-1) system is a central mediator of innate immunity and inflammation, and its receptor-binding step is the first committed event in IL-1 signal transduction.
• IL-1 receptor binding is tightly controlled by the naturally occurring antagonist IL-1RA, which competes with IL-1 for receptor occupancy without activating the receptor.
• The IL-1 receptor family includes activating receptors (IL-1R1, IL-1RAP) and inhibitory/decoy receptors (IL-1R2), so binding can either trigger or dampen signaling depending on the receptor context.
• Dysregulated IL-1 receptor binding contributes to inflammatory diseases, kidney disease and cancer progression, making it a validated drug target.
• CRISPR knockout, point-mutation, knock-in and overexpression models are powerful tools to dissect which receptor-binding events drive a given phenotype.
Description
Interleukin-1 (IL-1) is one of the most pleiotropic cytokines in immunology, and its biological effects begin with a single molecular event: binding to an interleukin-1 receptor. GO:0005149, interleukin-1 receptor binding, captures exactly this function. It is defined as binding to an interleukin-1 receptor, and it is the molecular gateway through which IL-1 family ligands communicate with cells. Because the IL-1 receptor family contains both signaling-competent and decoy receptors, the same binding function can lead to completely different cellular outcomes depending on which receptor is engaged. The IL-1 receptor family is large and structurally conserved, and its members are expressed on a wide range of immune and non-immune cells. The interaction between IL-1 and its receptor was recognized early as a key step in inflammatory signaling, and it remains a paradigm for cytokine-receptor recognition. The functional consequences of this binding event include recruitment of the IL-1 receptor accessory protein (IL-1RAP), activation of NF-kB and MAP kinase pathways, and induction of downstream inflammatory genes. For researchers, GO:0005149 is important because it sits at the interface between ligand biology and receptor biology. Understanding which ligands bind which receptors, and how that binding is regulated, is essential for interpreting experiments in inflammation, cancer, kidney disease and host defense. This article summarizes the authoritative definition, the molecular mechanism, the key genes and the experimental methods used to study interleukin-1 receptor binding.
interleukin-1 receptor binding At A Glance
| GO ID | GO:0005149 |
|---|---|
| GO term | interleukin-1 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-1; interleukin-1 receptor ligand |
| Definition | Binding to an interleukin-1 receptor. |
| Major function | Mediates the first step of IL-1 family cytokine recognition and signal initiation or inhibition. |
| Key ligands | IL-1 alpha, IL-1 beta, IL-1RA and other IL-1 family cytokines. |
| Key receptors | IL-1R1, IL-1R2, IL-1RAP and related family members. |
| Related disease areas | Inflammation, kidney disease, cancer and host defense. |
What Is GO:0005149?
GO:0005149 interleukin-1 receptor binding is a molecular function term that describes the selective, non-covalent interaction of a ligand with an interleukin-1 receptor. In practice, this includes binding of IL-1 family cytokines such as IL-1 alpha and IL-1 beta to receptors of the IL-1 receptor family, as well as binding of the endogenous antagonist IL-1RA to the same receptors. The term does not by itself specify whether binding activates or inhibits signaling; that depends on the identity of the receptor and the presence of co-receptors such as IL-1RAP.
Why Is interleukin-1 receptor binding Important in Cell Biology?
Interleukin-1 receptor binding is important because it is the molecular decision point that determines whether a cell responds to IL-1 family cytokines. Because the IL-1 system controls fever, acute-phase responses, immune cell recruitment and tissue remodeling, the binding step is a major node for therapeutic intervention. The existence of a natural antagonist, IL-1RA, demonstrates that blocking this binding event is a validated strategy for controlling inflammation. In addition, the receptor family includes decoy and accessory proteins, so the same binding function can be harnessed for either activation or inhibition depending on context.
• IL-1 receptor binding initiates inflammatory signaling that is central to innate immunity.
• The natural antagonist IL-1RA competes for the same binding site and provides a built-in regulatory mechanism.
• IL-1RAP acts as a co-receptor that is required for productive signaling after ligand binding.
• IL-1R2 functions as a decoy receptor, so binding to IL-1R2 can sequester ligand rather than activate cells.
• Dysregulated IL-1 receptor binding is implicated in kidney disease and renal inflammation.
• IL-1RAP is being explored as an immunotherapy target in human malignancies.
• The IL-1 receptor family is structurally conserved and serves as a model for cytokine-receptor recognition.
• Early biochemical studies established the IL-1/IL-1-receptor interaction as a direct binding event.
• Understanding receptor binding helps interpret experiments using IL-1 blockade or receptor antagonists.
• CRISPR-based models allow causal testing of which receptor-binding interactions drive disease.
Molecular Mechanism of interleukin-1 receptor binding
Ligand recognition by IL-1 receptors
In simple terms: The first step is the ligand physically docking onto the receptor.
Interleukin-1 receptor binding begins when an IL-1 family ligand, such as IL-1 alpha or IL-1 beta, engages the extracellular domain of an IL-1 receptor. This interaction is non-covalent and depends on complementary surfaces between the ligand and the receptor. The IL-1 receptor family shares conserved structural features that support this recognition event. Early studies established that the IL-1/IL-1-receptor interaction is a direct and specific binding event.
Receptor selectivity and decoy binding
In simple terms: Different receptors can bind the same ligand but produce different outcomes.
IL-1 receptor binding is not limited to activating receptors. IL-1R2 is a decoy receptor that can bind IL-1 family ligands without initiating signaling, thereby modulating the availability of free ligand. This means that the same molecular function, interleukin-1 receptor binding, can lead to either signal initiation or signal sequestration depending on which receptor is engaged. The balance between activating and decoy receptors is therefore a key determinant of cellular responses.
Co-receptor recruitment and signaling initiation
In simple terms: After the ligand binds, a helper receptor joins to start the signal.
Productive signaling typically requires recruitment of the IL-1 receptor accessory protein (IL-1RAP) to the ligand-receptor complex. IL-1RAP is essential for downstream activation of NF-kB and MAP kinase pathways, and its role has been documented in several inflammatory conditions. In malignancies, IL-1RAP has been proposed as a therapeutic target because of its contribution to tumor-promoting signaling. Thus, interleukin-1 receptor binding is often a prerequisite for co-receptor assembly and signal transduction.
Antagonism by IL-1RA
In simple terms: A natural blocker can occupy the receptor without turning it on.
The interleukin-1 receptor antagonist (IL-1RA) binds to IL-1 receptors but does not activate them, thereby competing with IL-1 alpha and IL-1 beta for the same binding site. This competitive antagonism is a physiological mechanism for limiting IL-1-driven inflammation. Because IL-1RA uses the same binding function defined by GO:0005149, it illustrates that receptor occupancy alone is not sufficient for activation.
Regulation of binding availability
In simple terms: Cells control how much ligand and receptor are available to bind.
The extent of interleukin-1 receptor binding is influenced by the expression levels of ligands, receptors and decoy proteins. IL-1R2 can act as a sink for IL-1 family ligands, reducing the amount available to engage activating receptors. IL-1RA provides an additional layer of regulation by competing for receptor occupancy. Together, these mechanisms tune the sensitivity of cells to IL-1 family cytokines.
Key Genes Involved in GO:0005149 interleukin-1 receptor binding
The genes and proteins most directly associated with GO:0005149 include IL-1 family ligands, their receptors and the accessory/decoy proteins that shape the binding outcome.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1B | Encodes IL-1 beta, a major ligand that binds IL-1 receptors. | Central to inflammatory disease models and cytokine release studies. |
| IL1A | Encodes IL-1 alpha, a ligand that binds IL-1 receptors. | Used to study membrane-bound and secreted IL-1 signaling. |
| IL1RN | Encodes IL-1RA, the natural antagonist that binds IL-1 receptors without activating them. | Key tool for anti-inflammatory studies and receptor blockade. |
| IL1R1 | Encodes the primary signaling receptor for IL-1. | Main target for knockout and point-mutation studies of IL-1 signaling. |
| IL1R2 | Encodes a decoy receptor that binds IL-1 family ligands. | Important for studying ligand sequestration in kidney disease. |
| IL1RAP | Encodes the IL-1 receptor accessory protein required for signaling. | Therapeutic target in inflammatory conditions and cancer. |
| IL1RL1 | Encodes a member of the IL-1 receptor family. | Used to study family-wide receptor binding specificity. |
| IL1RL2 | Encodes a member of the IL-1 receptor family. | Relevant to IL-1 family ligand-receptor mapping. |
| IL18R1 | Encodes a receptor for IL-18, a member of the IL-1 family. | Used to compare binding across IL-1 receptor family members. |
| IL18RAP | Encodes an accessory protein for IL-18 receptor signaling. | Model for accessory protein function in the IL-1 family. |
| IL36RN | Encodes an IL-1 family antagonist. | Used to study antagonist-based regulation of receptor binding. |
| MYD88 | Encodes an adaptor downstream of IL-1 receptor activation. | Readout of productive IL-1 receptor binding and signaling. |
| NFKB1 | Encodes a transcription factor activated downstream of IL-1 receptor binding. | Used to measure signaling output after receptor engagement. |
| TIRAP | Encodes an adaptor involved in IL-1 receptor signaling. | Helps dissect signaling versus binding events. |
| IRAK4 | Encodes a kinase recruited after IL-1 receptor activation. | Used to study post-binding signal propagation. |
| TRAF6 | Encodes an E3 ligase downstream of IL-1 receptor signaling. | Marker of productive receptor engagement. |
| NLRP3 | Encodes an inflammasome component that promotes IL-1 beta maturation. | Links IL-1 receptor binding to inflammasome biology. |
| CASP1 | Encodes caspase-1, which processes IL-1 beta. | Used to study ligand availability for receptor binding. |
How Is interleukin-1 receptor binding Regulated?
Interleukin-1 receptor binding is regulated at multiple levels. The expression levels of IL-1 ligands, activating receptors, decoy receptors and the antagonist IL-1RA determine how much productive binding can occur. IL-1RA competes directly with IL-1 alpha and IL-1 beta for receptor occupancy, providing a natural brake on signaling. IL-1R2 acts as a decoy receptor that can bind IL-1 family ligands and reduce their availability to activating receptors. In addition, the presence of IL-1RAP is required for productive signaling after ligand binding, so co-receptor expression is a further regulatory layer. Together, these mechanisms tune the sensitivity of cells to IL-1 family cytokines.
interleukin-1 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1R2 | Kidney disease and renal inflammation | IL1R2 knockout or overexpression in renal cell models |
| IL1RAP | Human malignancies and inflammatory conditions | IL1RAP knockout or knockdown in tumor and immune cells |
| IL1RN | Inflammation driven by unopposed IL-1 signaling | IL1RN knockout or point-mutation models |
| IL1R1 | IL-1-driven inflammatory signaling | IL1R1 knockout and receptor-binding point mutants |
| IL1B | Inflammatory cytokine release and inflammasome biology | IL1B knockout or overexpression models |
Interleukin-1 receptor binding in kidney disease
IL-1 receptor 2 (IL-1R2) has been implicated in kidney disease, where it can modulate IL-1 availability and inflammatory injury. Because IL-1R2 binds IL-1 family ligands without activating signaling, changes in its expression can shift the balance between inflammation and resolution in renal tissue. This makes interleukin-1 receptor binding a relevant axis for studying kidney inflammation and potential therapeutic targeting.
Interleukin-1 receptor binding in cancer and immunotherapy
IL-1RAP, the accessory protein required for productive IL-1 receptor signaling, has been proposed as a target for immunotherapy of human malignancies. Its role in certain inflammatory conditions further supports the idea that blocking IL-1 receptor binding or co-receptor recruitment could have therapeutic benefit. These findings link GO:0005149 to tumor immunology and to the development of receptor-directed biologics.
Interleukin-1 receptor binding in inflammatory conditions
The IL-1 system is a core mediator of inflammation, and the natural antagonist IL-1RA demonstrates that interfering with receptor binding can control inflammatory responses. IL-1RAP has been studied in several inflammatory conditions, where it contributes to signal amplification after ligand binding. Understanding the binding step is therefore central to interpreting both physiological and pathological inflammation.
From interleukin-1 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL1R1 abolish IL-1 receptor binding and signaling? | IL1R1 knockout cell line |
| Does IL1RAP recruitment require ligand binding to IL1R1? | IL1RAP tagged knock-in and co-immunoprecipitation |
| Does IL1R2 act as a decoy for IL-1 family ligands? | IL1R2 overexpression and ligand-binding assays |
| Which residues in IL1R1 mediate ligand binding? | IL1R1 point-mutation knock-in |
| Can IL-1RA block IL-1 receptor binding in a disease model? | IL1RN overexpression or recombinant IL-1RA treatment |
| Which genes are required for productive IL-1 receptor signaling? | CRISPR library screening in IL-1-stimulated cells |
How to Study the interleukin-1 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled ligand binding | Direct ligand-receptor interaction | Characterizing IL-1 receptor binding affinity |
| Co-immunoprecipitation | Physical interaction between ligand and receptor | Confirming IL-1RAP recruitment |
| Proximity labeling | Spatially restricted protein interactions | Detecting receptor complexes after ligand binding |
| NF-kB reporter assay | Downstream signaling activation | Functional readout of productive binding |
| Phospho-MAPK immunoblot | Kinase pathway activation | Confirming signaling after receptor engagement |
| CRISPR knockout | Loss-of-function phenotype | Testing receptor requirement in disease models |
| CRISPR point mutation | Specific residue function | Mapping ligand-binding interfaces |
| Overexpression | Gain-of-function phenotype | Testing decoy receptor effects |
Ligand-receptor binding assays
Direct binding assays, such as radiolabeled or fluorescently labeled ligand binding, are used to measure interleukin-1 receptor binding affinity and specificity. These methods can distinguish binding to activating receptors from binding to decoy receptors such as IL-1R2. They are foundational for characterizing IL-1 family ligand-receptor pairs.
Co-immunoprecipitation and proximity assays
Co-immunoprecipitation and proximity labeling can detect the interaction between IL-1 ligands and their receptors, as well as recruitment of IL-1RAP after binding. These approaches are useful for confirming that a candidate receptor engages a given ligand in a cellular context. They also help distinguish binding from downstream signaling events.
Transcriptional and signaling readouts
Because productive interleukin-1 receptor binding leads to NF-kB and MAP kinase activation, reporter assays and phospho-protein analysis are commonly used as functional readouts. These methods measure the consequence of binding rather than binding itself, and they are often combined with receptor knockout or knockdown. They are especially useful in inflammatory and cancer models.
CRISPR-based perturbation
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of which receptor-binding events matter in a given phenotype. For example, knocking out IL1RAP can reveal whether co-receptor recruitment is required for a response. These models are increasingly used to dissect IL-1 receptor biology in disease-relevant cells.
How CRISPR Can Be Used to Study GO:0005149 interleukin-1 receptor binding
Knockout
CRISPR knockout of IL1R1, IL1RAP or IL1R2 can determine which receptor components are required for interleukin-1 receptor binding and downstream signaling. For example, IL1RAP knockout can reveal whether co-receptor recruitment is essential for a given inflammatory response. Knockout models are also useful for validating receptor dependency in cancer and kidney disease contexts.
Point Mutation
Point mutations in receptor genes can be used to map the residues that mediate ligand binding. By introducing specific amino acid substitutions, researchers can separate binding from signaling and test structure-function hypotheses. This approach is particularly informative for conserved residues in the IL-1 receptor family.
Knock-in
Knock-in of tags or reporters into IL1R1, IL1RAP or IL1R2 allows visualization and biochemical isolation of receptor complexes after ligand binding. Tagged knock-in models can be combined with co-immunoprecipitation or imaging to track receptor engagement in native cells. This is valuable for studying dynamic receptor assembly.
Overexpression
Overexpression of IL1RN or IL1R2 can be used to test whether increasing antagonist or decoy availability reduces interleukin-1 receptor binding and signaling. Overexpression models are also useful for gain-of-function studies of IL-1 family ligands. These models complement knockout approaches by probing the opposite direction of perturbation.
How EDITGENE Supports interleukin-1 receptor binding Research
Researchers studying interleukin-1 receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation or disease progression. EDITGENE provides the CRISPR tools and bioinformatics support needed to move from correlation to causation in IL-1 receptor biology.
Contact EDITGENE today to design your custom CRISPR model for interleukin-1 receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IL1B Knockout HEK293 Cell Line | EDJ-KQ140 | Human | 3553 | Details Get a Quote |
| IRAK4 Knockout HEK293 Cell Line | EDJ-KQ569 | Human | 51135 | Details Get a Quote |
| MYD88 Knockout HEK293 Cell Line | EDJ-KQ578 | Human | 4615 | Details Get a Quote |
| IL1A Knockout HEK293 Cell Line | EDJ-KQ676 | Human | 3552 | Details Get a Quote |
| IL37 Knockout HEK293 Cell Line | EDJ-KQ1410 | Human | 27178 | Details Get a Quote |
| IL36RN Knockout HEK293 Cell Line | EDJ-KQ2688 | Human | 26525 | Details Get a Quote |
| IL1RN Knockout HEK293 Cell Line | EDJ-KQ3032 | Human | 3557 | Details Get a Quote |
| TLR5 Knockout HEK293 Cell Line | EDJ-KQ5938 | Human | 7100 | Details Get a Quote |
| TRIP6 Knockout HEK293 Cell Line | EDJ-KQ5963 | Human | 7205 | Details Get a Quote |
| IL36A Knockout HEK293 Cell Line | EDJ-KQ7970 | Human | 27179 | Details Get a Quote |
| IL36B Knockout HEK293 Cell Line | EDJ-KQ8709 | Human | 27177 | Details Get a Quote |
| IL1F10 Knockout HEK293 Cell Line | EDJ-KQ10143 | Human | 84639 | Details Get a Quote |
| IL36G Knockout HEK293 Cell Line | EDJ-KQ13828 | Human | 56300 | Details Get a Quote |
| IL1A Knockout HeLa Cell Line | EDJ-KQ18112 | Human | 3552 | Details Get a Quote |
| IL1B Knockout HeLa Cell Line | EDJ-KQ18960 | Human | 3553 | Details Get a Quote |
Displaying Records 1 To 15 Of 57 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About interleukin-1 receptor binding
What is GO:0005149 interleukin-1 receptor binding?
GO:0005149 is a molecular function term describing the binding of a ligand to an interleukin-1 receptor, including IL-1 family cytokines and the antagonist IL-1RA.
What genes are involved in interleukin-1 receptor binding?
Key genes include IL1A, IL1B, IL1RN, IL1R1, IL1R2 and IL1RAP, which encode ligands, receptors and accessory proteins in the IL-1 system.
Which receptors bind interleukin-1?
IL-1R1 is the primary signaling receptor, IL-1R2 acts as a decoy receptor, and IL-1RAP serves as an essential co-receptor for signaling.
How is interleukin-1 receptor binding regulated?
It is regulated by the expression of ligands, receptors and decoy proteins, and by the natural antagonist IL-1RA, which competes for receptor occupancy.
What happens after interleukin-1 binds its receptor?
Ligand binding typically recruits IL-1RAP and activates NF-kB and MAP kinase pathways, leading to inflammatory gene expression.
Is interleukin-1 receptor binding involved in disease?
Yes, dysregulated binding contributes to kidney disease, inflammatory conditions and cancer progression.
What is the role of IL-1RA in receptor binding?
IL-1RA binds IL-1 receptors without activating them, acting as a competitive antagonist of IL-1 alpha and IL-1 beta.
What is the role of IL-1R2 in receptor binding?
IL-1R2 is a decoy receptor that binds IL-1 family ligands and can reduce their availability to activating receptors.
How can CRISPR be used to study interleukin-1 receptor binding?
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of receptor and ligand function in disease-relevant cells.
Why is interleukin-1 receptor binding important for immunotherapy?
IL-1RAP is required for productive signaling and has been proposed as a target for immunotherapy of human malignancies.
Conclusion
GO:0005149 interleukin-1 receptor binding defines the molecular event that initiates IL-1 family cytokine signaling and shapes inflammatory, renal and cancer-related biology. Its regulation by IL-1RA and decoy receptors such as IL-1R2 highlights the importance of receptor context in determining cellular outcomes. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal evidence needed to translate this binding function into therapeutic insight.
References
- 1. Arend WP. 1993. Interleukin-1 receptor antagonist.. Adv Immunol 54:167-227 PMID: 8379462
- 2. Zarezadeh Mehrabadi A et al.. 2024. Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies.. Crit Rev Oncol Hematol 193:104200 PMID: 37981104
- 3. Hu H et al.. 2024. Role of Interleukin 1 Receptor 2 in Kidney Disease.. J Interferon Cytokine Res 44(4):170-177 PMID: 38527174
- 4. Boraschi D et al.. 2013. The interleukin-1 receptor family.. Semin Immunol 25(6):394-407 PMID: 24246227
- 5. MacDonald HR et al.. 1987. The interleukin-1/interleukin-1-receptor interaction.. Ann Inst Pasteur Immunol 138(3):482-5 PMID: 2958019
- 6. Zarezadeh Mehrabadi A et al.. 2022. The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions.. Immunology 166(1):38-46 PMID: 35231129
- 7. Stylianou E et al.. 1998. Interleukin-1.. Int J Biochem Cell Biol 30(10):1075-9 PMID: 9785472
